| Market Cap | ₹15,260 CrPharmaceuticals |
|---|---|
| Quarterly Revenue | ₹729.1 Cr30.4% YoY Growth |
| P/E TTM | 85.86Sector PE 43.58 |
| 1-Year Return | -33.31%Price Performance |
Key highlights
- Strategic Letter of Intent signed with Strand Life Sciences Private Limited
- Partner is a genomics research subsidiary of Reliance Industries Limited
- Collaboration aims to explore new healthcare delivery opportunities across India
- Company reported a 30.41% YoY increase in quarterly revenue to ₹729.1 Crore
- AstraZeneca confirmed the parties are not related and the LOI involves no related party transaction
A Strategic Alliance with Strand Life Sciences
AstraZeneca Pharma India has entered into a non-binding agreement with Strand Life Sciences Private Limited, a genomics research and diagnostics firm. Strand operates as a subsidiary of Reliance Industries Limited, marking a notable tie-up between the global pharmaceutical major's Indian arm and one of the country's largest conglomerate-backed diagnostic entities. The collaboration is designed to explore various opportunities within the Indian healthcare landscape, leveraging Strand's expertise in genomics to potentially enhance AstraZeneca's diagnostic and therapeutic reach in the region.
The execution of this Letter of Intent does not constitute a related party transaction.
Financial Performance and Valuation Context
The partnership announcement comes on the heels of strong quarterly results for the period ended September 30, 2026. AstraZeneca Pharma India reported an operating revenue of ₹729.1 Crore, representing a 30.41% growth compared to the same quarter last year. Net profit for the quarter stood at ₹62.33 Crore, surging 64.33% on a sequential basis.
While the company maintains a robust net profit TTM of ₹177.73 Crore, its valuation remains high with a P/E ratio of 85.86, nearly double the sector average of 43.58. The stock has faced pressure over the last year, declining 33.31% from its high.
Expanding the Indian Healthcare Ecosystem
- November 07, 2026: Confirmed rollout of breast cancer drug Datverzo in the Indian market
- October 14, 2026: Partnered with NIPER Raebareli to build clinical research capabilities at 25 sites
- July 28, 2026: Signed MoU with Andhra Pradesh for an Integrated Genomic Solutions Centre
- April 07, 2026: Collaborated with Telangana for AI-enabled lung cancer screening in 20 facilities
- November 17, 2025: Entered a ₹26.00 Crore distribution agreement with Sun Pharma for Lokelma
Official Disclosure on Collaboration
This is to inform that AstraZeneca Pharma India Limited has signed a Letter of Intent with Strand Life Sciences Private Limited, a genomics research and diagnostics company and a subsidiary of Reliance Industries Limited, to explore opportunities to collaborate in healthcare in India.
| Date | Announcement | Amount |
|---|---|---|
| 14 Oct 2026 | Partnership with NIPER Raebareli to build clinical research capabilities across 25 emerging clinical trial sites under Biopharma SHAKTISource: ddnews.gov.in | – |
| 28 Jul 2026 | MoU with the Government of Andhra Pradesh to establish an Integrated Genomic Solutions Centre and precision oncology ecosystem in AmaravatiSource: thehindu.com | – |
| 07 Apr 2026 | MoU with the Government of Telangana to deploy AI-enabled lung cancer screening across 20 public healthcare facilitiesSource: astrazeneca.in | – |
| 17 Nov 2025 | Distribution services agreement and second brand partnership with Sun Pharma for Sodium Zirconium Cyclosilicate (Lokelma/Gimliand)Source: sunpharma.com | ₹26.00 Cr |
What to watch next
- Commercial rollout of breast cancer drug Datverzo scheduled for late November 2026
- Updates on the Integrated Genomic Solutions Centre project in Andhra Pradesh
- Expansion of clinical research capabilities across the 25 NIPER-affiliated sites
- Next quarterly financial results expected in February 2027
| Share price | ₹6104 |
|---|---|
| Market capitalisation | ₹15,260.00 Cr |
| Revenue (annual) | ₹2,275.58 Cr |
| Net profit (annual) | ₹187.52 Cr |
| Revenue (latest quarter) | ₹729.10 Cr+6.78% vs previous quarter |
| Net profit (latest quarter) | ₹62.33 Cr+64.33% vs previous quarter |
| P/E (TTM) | 85.86×Sector 43.58× |
| Promoter holding | 75%0.00% QoQ |
| FII holding | 2.64%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by AstraZeneca Pharma India Limited announcing a Letter of Intent with Strand Life Sciences. Market figures from a third-party data provider.


